159 related articles for article (PubMed ID: 8869018)
1. An overview of the results of the EPIC trial.
Califf RM; Lincoff AM; Tcheng JE; Topol EJ
Eur Heart J; 1995 Nov; 16 Suppl L():43-9. PubMed ID: 8869018
[TBL] [Abstract][Full Text] [Related]
2. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
EPIC Investigators
N Engl J Med; 1994 Apr; 330(14):956-61. PubMed ID: 8121459
[TBL] [Abstract][Full Text] [Related]
3. Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications.
Lefkovits J; Blankenship JC; Anderson KM; Stoner GL; Talley JD; Worley SJ; Weisman HF; Califf RM; Topol EJ
J Am Coll Cardiol; 1996 Oct; 28(4):849-55. PubMed ID: 8837559
[TBL] [Abstract][Full Text] [Related]
4. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
Lincoff AM; Califf RM; Anderson KM; Weisman HF; Aguirre FV; Kleiman NS; Harrington RA; Topol EJ
J Am Coll Cardiol; 1997 Jul; 30(1):149-56. PubMed ID: 9207636
[TBL] [Abstract][Full Text] [Related]
5. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators.
Lefkovits J; Ivanhoe RJ; Califf RM; Bergelson BA; Anderson KM; Stoner GL; Weisman HF; Topol EJ
Am J Cardiol; 1996 May; 77(12):1045-51. PubMed ID: 8644655
[TBL] [Abstract][Full Text] [Related]
6. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
Ghaffari S; Kereiakes DJ; Lincoff AM; Kelly TA; Timmis GC; Kleiman NS; Ferguson JJ; Miller DP; Califf RA; Topol EJ
Am J Cardiol; 1998 Jul; 82(1):7-12. PubMed ID: 9671000
[TBL] [Abstract][Full Text] [Related]
7. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators.
Topol EJ; Califf RM; Weisman HF; Ellis SG; Tcheng JE; Worley S; Ivanhoe R; George BS; Fintel D; Weston M
Lancet; 1994 Apr; 343(8902):881-6. PubMed ID: 7908357
[TBL] [Abstract][Full Text] [Related]
8. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.
Mak KH; Challapalli R; Eisenberg MJ; Anderson KM; Califf RM; Topol EJ
Am J Cardiol; 1997 Oct; 80(8):985-8. PubMed ID: 9352964
[TBL] [Abstract][Full Text] [Related]
9. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
Topol EJ; Ferguson JJ; Weisman HF; Tcheng JE; Ellis SG; Kleiman NS; Ivanhoe RJ; Wang AL; Miller DP; Anderson KM; Califf RM
JAMA; 1997 Aug; 278(6):479-84. PubMed ID: 9256222
[TBL] [Abstract][Full Text] [Related]
10. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
11. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
EPILOG Investigators
N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
[TBL] [Abstract][Full Text] [Related]
12. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.
Marmur JD; Mitre CA; Barnathan E; Cavusoglu E
Am Heart J; 2006 Nov; 152(5):876-81. PubMed ID: 17070148
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group.
Simoons ML; de Boer MJ; van den Brand MJ; van Miltenburg AJ; Hoorntje JC; Heyndrickx GR; van der Wieken LR; de Bono D; Rutsch W; Schaible TF
Circulation; 1994 Feb; 89(2):596-603. PubMed ID: 7508826
[TBL] [Abstract][Full Text] [Related]
14. A risk-benefit assessment of abciximab in angioplasty.
Kleiman NS
Drug Saf; 1999 Jan; 20(1):43-57. PubMed ID: 9935276
[TBL] [Abstract][Full Text] [Related]
15. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study.
Lancet; 1997 May; 349(9063):1429-35. PubMed ID: 9164316
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty.
Chen YH; Chen JW; Wu TC; Ding PY; Wang SP; Chang MS
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan; 63(1):8-15. PubMed ID: 10645045
[TBL] [Abstract][Full Text] [Related]
17. [Use of abciximab during coronary angioplasty].
Philippe F; Montalescot G; Drobinski G; Thomas D
Arch Mal Coeur Vaiss; 1997 Dec; 90(12):1645-50. PubMed ID: 9587446
[TBL] [Abstract][Full Text] [Related]
18. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.
Ibbotson T; McGavin JK; Goa KL
Drugs; 2003; 63(11):1121-63. PubMed ID: 12749745
[TBL] [Abstract][Full Text] [Related]
19. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group.
Berkowitz SD; Sane DC; Sigmon KN; Shavender JH; Harrington RA; Tcheng JE; Topol EJ; Califf RM
J Am Coll Cardiol; 1998 Aug; 32(2):311-9. PubMed ID: 9708455
[TBL] [Abstract][Full Text] [Related]
20. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
Ibbotson T; McGavin JK; Goa KL
Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
